Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein.
Hepatitis C Virus (HCV) infects 200 million individuals worldwide. Although several FDA approved drugs targeting the HCV serine protease and polymerase have shown promising results, there is a need for better drugs that are effective in treating a broader range of HCV genotypes and subtypes without...
Main Authors: | Reem R Al Olaby, Laurence Cocquerel, Adam Zemla, Laure Saas, Jean Dubuisson, Jost Vielmetter, Joseph Marcotrigiano, Abdul Ghafoor Khan, Felipe Vences Catalan, Alexander L Perryman, Joel S Freundlich, Stefano Forli, Shoshana Levy, Rod Balhorn, Hassan M Azzazy |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4214736?pdf=render |
Similar Items
-
CD81 and Hepatitis C Virus (HCV) Infection
by: Lucie Fénéant, et al.
Published: (2014-02-01) -
HCV Glycoprotein Structure and Implications for B-Cell Vaccine Development
by: Luisa J. Ströh, et al.
Published: (2020-09-01) -
Glucosidase inhibitors induce HCV glycoproteins misfolding, impair viral assembly and release, and reduce the infectivity of residually secreted HCV particles
by: Chapel, C, et al.
Published: (2006) -
Optimized Hepatitis C Virus (HCV) E2 Glycoproteins and their Immunogenicity in Combination with MVA-HCV
by: María Q. Marín, et al.
Published: (2020-08-01) -
HCV-Specific T Cell Responses During and After Chronic HCV Infection
by: Hendrik Luxenburger, et al.
Published: (2018-11-01)